Sorrento Therapeutics. has been granted a patent for aqueous pharmaceutical compositions that enable sustained release of corticosteroids. The compositions, designed for various injection methods, include both insoluble and soluble corticosteroids, along with viscosity enhancers like sodium hyaluronate, to treat inflammation and pain. GlobalData’s report on Sorrento Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sorrento Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. Sorrento Therapeutics's grant share as of June 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Sustained release corticosteroid compositions for pain treatment
The granted patent US12016867B2 outlines a method for treating inflammation and pain through the intra-articular injection of a specific aqueous pharmaceutical composition. This composition includes both an insoluble and a soluble corticosteroid, specifically selected from salts and esters of dexamethasone, alongside at least one viscosity-enhancing agent, which can be sodium hyaluronate or hyaluronic acid. The viscosity-enhancing agent must have a molecular weight between 1.0 MDa and 2.5 MDa and be present in concentrations ranging from 1.0% w/v to 1.5% w/v. The patent further specifies that the soluble corticosteroid is preferably dexamethasone sodium phosphate, while the insoluble counterpart is dexamethasone acetate.
Additional claims detail the optimal ratios of the corticosteroids, with a weight or molar ratio ranging from 1:4 to 4:1, and suggest specific viscosity ranges for the composition, between 10 kcP and 200 kcP. The patent also provides parameters for the injection process, indicating that less than 27 N of force should be used, ideally less than 20 N, and that the injection rate should be approximately 0.5 inches per minute. Furthermore, it is noted that the treatment can be administered once every 4 to 24 weeks, with a target dexamethasone concentration of about 5 mg/mL in the composition. This method aims to enhance the efficacy and comfort of intra-articular injections for individuals suffering from inflammatory conditions.
To know more about GlobalData’s detailed insights on Sorrento Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
